Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Sponsor: Hunan Province Tumor Hospital
Summary
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
Official title: Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors With or Without Chemotherapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12000
Start Date
2021-10-01
Completion Date
2027-09-14
Last Updated
2024-08-02
Healthy Volunteers
No
Conditions
Interventions
Pemetrexed plus Pembrolizumab
Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days
Pembrolizumab
Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.
Pemetrexed
Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.
Locations (1)
Hunan Cancer Hospital
Changsha, Hunan, China